Selecting and Sequencing Therapies to Improve Outcomes in Patients With Lymphoma

June 18th 2025

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Real-World Axicabtagene Ciloleucel Shows Consistent Efficacy, Safety in R/R LBCL

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

$A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.$

Courtney Flaherty

June 17th 2025

Highlighting Insights From the Marginal Zone Lymphoma Workshop

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

$JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL$

Polatuzumab Vedotin Combo Improves OS Vs Rituximab/Chemo in R/R DLBCL

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Ariana Pelosci

FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma

Patients with R/R DLBCL given polatuzumab vedotin, rituximab, gemcitabine, and oxaliplatin had an OS of 19.5 months.

Related Content

June 18th 2025

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Real-World Axicabtagene Ciloleucel Shows Consistent Efficacy, Safety in R/R LBCL

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

$A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.$

Courtney Flaherty

June 17th 2025

Highlighting Insights From the Marginal Zone Lymphoma Workshop

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

$JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL$

Polatuzumab Vedotin Combo Improves OS Vs Rituximab/Chemo in R/R DLBCL

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Ariana Pelosci